International Cancer Proteogenomics Symposium

Event Day: 2nd March, 2023

Zoom Online

Hosted by National Cancer Center Tokyo, Japan

Proteogenomics will further our understanding of the molecular backgrounds of clinical observations, promote the characterization of tumors, and generate the biomarkers for precision medicine. Integration of genome, transcriptome, and proteome data is the basic strategy of proteogenomics, and all clinically relevant information will be required to explore the significance of the integrated data. Thus, the international and multidisciplinary approach is the essential strategy to make the best use of proteogenomics data. The basic and clinical researchers should work together, aiming the common research outcome, that is, the benefits of patients with cancers.

Welcome

I would like to deliver my warm greetings and heartfelt welcome to all Participants of the International Cancer Proteogenomics Symposium. This workshop is designed to share the knowledge of cancer proteogenomics, and to facilitate the collaboration of researchers who are interested in the clinical applications of proteogenomic data.

In this century, the outcome of basic and clinical research in the last decades has led to remarkable progress in treatments, and the molecular targeted therapy, cancer genomic medicine and cancer immune therapy are widely used in the clincal practice. Multiple treatment options are available for single types of malignancies, and the patients with similar cancers demonstrate the different response to treatments. Therefore, we need modalities to capture the important characters of cancers for precise diagnosis, and optimize the therapeutic strateiges for individual cancer patients. Moreover, adequate therapeutic strategies are currently established only in the limited types of cancers, and novel therapy has long been desired for a considerable number of patients with rare cancers. More efforts will be requred for the patients who suffer from cancers. Cancer proteogenomics will offer the opportunities to develop novel diagnostic and therpeutic modalities.

The International Cancer Proteogenomics Symposium will welcome participants from the basic and clinical researchers in academia or industry. The meeting will provide an excellent opportunity to exchange and share a wide range of the ideas for cancer proteogenomics toward clinical applications. The workshop will promote the international collaboration and cooperation among the researchres who aim the benefits of cancer patients.

We are looking forward to your participation in our Symposium.

Tadashi Kondo, MD, PhD

Division of Rare Cancer Research

National Cancer Center, Tokyo, Japan

2nd March, Program Schedule

Time

Program & Speaker

8:00-8:10

（1st March, 18:00-18:10 (EST (UTC-5)).

Opening Remarks

Hiroyuki Mano, NCC, Japan

8:10-9:40

(1st March, 18:10-19:40 (EST (UTC-5))

Session 1: Cancer Proteogenomics for Precision Medicine

Chair, Hiroyuki Mano, NCC, Japan

International Collaboration in the Age of Precision Medicine [Cancer Moonshot Proteogenomics]

Henry Rodriguez, NCI, USA

Proteogenomic analysis of longitudinal trajectory of glioblastoma evolution

Jong Bae Park, NCC, Korea

Patient-derived cancer models for pharmaco-proteogenomics in rare cancers

Tadashi Kondo, NCC, Japan

09:40-09:50

Break Time

09:50-10:40

(1st March, 19:50-20:40

(EST (UTC-5))

Plenary session 1

Chair, Tadashi Kondo, NCC, Japan

The ProCan® pan-cancer knowledge base of proteomic and clinical data

Roger Reddel, ProCan, Children's Medical Research Institute, Australia

10:40-10:50

Break Time

10:50-11:40

(1st March, 20:50-21:40 (EST (UTC-5))

Plenary session 2

Chair, Koichi Ogura, NCC, Japan

Insights from routine, large scale clinical cancer genomic testing of sarcomas

Marc Ladanyi, Memorial Sloan Kettering Cancer Center, USA

11:40-12:00

Lunch Time

12:00-14:30

(1st March, 22:00-00:30 (EST (UTC-5))

Session 2: Molecular characterization of sarcoma for clinical application

Chair, Rei Noguchi, NCC, Japan

Genomic Landscape of Actionable Alterations in Bone and Soft Tissue Sarcomas: Report from the Center for Cancer Genomics and Advanced Therapeutics(C-CAT) database

Koichi Ogura, NCC, Japan

Genomic characterization of sarcomas for novel therapy

Koichi Matsuda, University of Tokyo, Japan

Proteogenomic profiling of myxoid liposarcoma

Koji Ueda, Japanese Foundation of Cancer Research, Japan

Study of SS18-SSX fusion-independent vulnerabilities in synovial sarcoma

Le Su, Jacksonville State University, USA

Molecular characterization of CIC-DUX4 sarcomas toward novel therapy

Ross Okimoto, University of California San Francisco, USA

14:30-14:40

Break Time

14:40-16:10